Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)

SHA:688163 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	44.29	38.77	64.2	76.48
Depreciation & Amortization	19.97	17.16	14.9	15.04
Other Amortization	0.37	0.24	0.24	0.24
Loss (Gain) From Sale of Assets	-1.44	-	-	0.25
Asset Writedown & Restructuring Costs	1.03	0.02	-0.95	1.02
Loss (Gain) From Sale of Investments	1.01	-10.33	-16.04	0.79
Provision & Write-off of Bad Debts	0.74	0.79	-0.53	0.6
Other Operating Activities	3.21	4.39	0.19	0.83
Change in Accounts Receivable	-10.42	-22.99	3.2	-4.48
Change in Inventory	-1.56	6.13	-4.33	-0.48
Change in Accounts Payable	-4.32	-0.5	7.87	1
Change in Other Net Operating Assets	-	-	-	0.79
Operating Cash Flow	50.25	32.82	67.91	92.29
Operating Cash Flow Growth	53.12%	-51.67%	-26.41%	-6.17%
Capital Expenditures	-59.37	-28.67	-26.46	-27.61
Sale of Property, Plant & Equipment	0.01	0.02	-	0.33
Investment in Securities	70.83	-305	-349.85	-65
Other Investing Activities	5.27	17.71	15.89	1.76
Investing Cash Flow	16.73	-315.94	-360.42	-90.52
Long-Term Debt Repaid	-1.15	-0.69	-1.34	-1.31
Net Debt Issued (Repaid)	-1.15	-0.69	-1.34	-1.31
Issuance of Common Stock	-	-	790.61	-
Common Dividends Paid	-34.63	-81.16	-97.39	-
Dividends Paid	-34.63	-81.16	-97.39	-
Other Financing Activities	-	-	-	-2.7
Financing Cash Flow	-35.77	-81.84	691.87	-4.01
Foreign Exchange Rate Adjustments	-0.03	0.16	0.49	-0.12
Net Cash Flow	31.19	-364.81	399.85	-2.36
Free Cash Flow	-9.12	4.15	41.46	64.68
Free Cash Flow Growth	-	-90.00%	-35.91%	-19.58%
Free Cash Flow Margin	-4.68%	2.18%	23.79%	30.99%
Free Cash Flow Per Share	-0.08	0.04	0.41	0.80
Cash Income Tax Paid	13.33	25.02	12.86	16.85
Levered Free Cash Flow	-23.72	-3.9	32.16	34.48
Unlevered Free Cash Flow	-23.45	-3.5	32.58	34.93
Change in Working Capital	-18.93	-18.22	5.9	-2.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.